1 |
Mitsiades N, Mitsiades CS, Richardson PG, et al (2003). Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101, 4055-62.
DOI
|
2 |
Nishimoto N, Kishimoto T (2006). Interleukin 6: from bench to bedside. Nature Clin Practice Rheumatol, 2, 619-26.
DOI
|
3 |
Park JK, Cho CH, Ramachandran S, et al (2006). Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line. Cancer Res Treatment, 38, 112-7.
DOI
|
4 |
Reagan MR, Ghobrial IM (2012). Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clinical Cancer Res, 18, 342-9.
DOI
|
5 |
Secrist J, Zhou X, Richon V (2003). HDAC inhibitors for the treatment of cancer. Current opinion in investigational drugs (London, England: 2000), 4, 1422-7.
|
6 |
Skov V, Larsen TS, Thomassen M, et al (2012). Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Lymphoma, 53, 123-9.
DOI
|
7 |
Smith EM, Boyd K, Davies FE (2010). The potential role of epigenetic therapy in multiple myeloma. British J Haematol, 148, 702-13.
DOI
|
8 |
Todoerti K, Lisignoli G, Storti P, et al (2010). Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Experimental hematology, 38, 141-53.
DOI
|
9 |
Van Damme M, Crompot E, Meuleman N, et al (2012). HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics, 7, 1403-12.
DOI
|
10 |
Gray SG, Ekstrom TJ (1998). Effects of cell density and trichostatin A on the Expression of HDAC1and p57Kip2in Hep 3B Cells. Biochemical Biophysical Res Communications, 245, 423-7.
DOI
|
11 |
Halkidou K, Gaughan L, Cook S, et al (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate, 59, 177-89.
DOI
|
12 |
Kaiser M, Zavrski I, Sterz J, et al (2006). The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, 91, 248-51.
|
13 |
Klein B, Bataille R (1992). Cytokine network in human multiple myeloma. Hematol/Oncol Clinics North America, 6, 273-84.
DOI
|
14 |
Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 2003. Elsevier, 21-33.
|
15 |
Lauta VM (2001). Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine, 16, 79-86.
DOI
|
16 |
Lemaire M, Deleu S, De Bruyne E, et al (2011). The microenvironment and molecular biology of the multiple myeloma tumor. Advances Cancer Res, 110, 20.
|
17 |
Lin RJ, Sternsdorf T, Tini M, et al (2001). Transcriptional regulation in acute promyelocytic leukemia. Oncogene, 20, 7204-15.
DOI
|
18 |
Lu Q, Lin X, Feng J, et al (2008). Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol, 9, 1-6.
|
19 |
Wang J, Hoshino T, Redner RL, et al (1998). ETO, fusion partner in t (8; 21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proceedings National Academy Sciences, 95, 10860-5.
DOI
|
20 |
Verdel A, Khochbin S (1999). Identification of a new family of higher eukaryotic histone deacetylases coordinate expression of differentiation-dependent chromatin modifiers. J Biological Chemistry, 274, 2440-5.
DOI
|
21 |
Weichert W (2009). HDAC expression and clinical prognosis in human malignancies. Cancer Letters, 280, 168-76.
DOI
|
22 |
Workman J, Kingston R (1998). Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annual Review Biochemistry, 67, 545-79.
DOI
|
23 |
Xu S, De Veirman K, Evans H, et al (2013). Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica, 34, 699-709.
DOI
|
24 |
Zhang Z, Yamashita H, Toyama T, et al (2004). HDAC6 expression is correlated with better survival in breast cancer.
|
25 |
De Becker A, Van Hummelen P, Bakkus M, et al (2007). Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica, 92, 440-9.
DOI
|
26 |
Minucci S, Pelicci PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6, 38-51.
DOI
|
27 |
Ashraf N, Zino S, Macintyre A, et al (2006). Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer, 95, 1056-61.
DOI
|
28 |
Bartl S, Taplick J, Lagger G, et al (1997). Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Molecular Cellular Biol, 17, 5033-43.
DOI
|
29 |
Bergfeld SA, DeClerck YA (2010). Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Reviews, 29, 249-61.
DOI
|
30 |
Catley L, Weisberg E, Tai YT, et al (2003). NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615-22.
DOI
|
31 |
Fandy TE, Shankar S, Ross DD, et al (2005). Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646-57.
DOI
|
32 |
Forsberg EC, Bresnick EH (2001). Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world*. Bioessays, 23, 820-30.
DOI
|
33 |
Goldstein RH, Reagan MR, Anderson K, et al (2010). Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res, 70, 10044-50.
DOI
|